XML 44 R38.htm IDEA: XBRL DOCUMENT
v3.25.3

Earnings Per Share (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Schedule of Potentially Dilutive Securities Not Included in the Computation of Diluted Net (Loss) Income Per Share of Common Stock | The following table presents potentially dilutive securities that were not included in the computation of diluted net (loss) income per share of common stock as their inclusion would have been anti-dilutive and or their issuance upon satisfying a contingency, if applicable, was not satisfied or deemed satisfied as of period end:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Akerna Common Warrants |  |  | 21,739 |  |  |  | - |  |  |  | 21,739 |  |  |  | — |
Akerna Underwriter Warrants |  |  | 1,087 |  |  |  | - |  |  |  | 1,087 |  |  |  | — |
Gryphon Warrants |  |  | 108,587 |  |  |  | - |  |  |  | 108,587 |  |  |  | — |
Total |  |  | 131,413 |  |  |  | - |  |  |  | 131,413 |  |  |  | — |
Summary of Reconciliation of the Denominator of the Basic and Diluted Net Income (Loss) Per Share of Common Stock Computations | The following is a reconciliation of the denominator of the basic and diluted net income (loss) per share of common stock computations for the periods presented:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
(in USD thousands, except share and per share amounts) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 3,475 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 168,773 |
Less: loss from discontinued operations (net of income tax benefit of nil, nil, nil, and $1.6 million, respectively) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,816 |
Net income from continuing operations – basic |  | $ | 3,475 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 173,589 |
Effect of dilutive shares on net income: |  |  |  |  |  |  |  |  |  |  |  |
Gryphon warrants revaluation included in net income (loss) (net of income tax benefit) (1) |  |  | (19 | ) |  |  | — |  |  |  | — |  |  |  | — |
Net income from continuing operations – diluted |  | $ | 3,456 |  |  | $ | (576 | ) |  | $ | (93,717 | ) |  | $ | 173,589 |
Loss from discontinued operations (net of income tax benefit of nil, nil, nil and $1.6 million, respectively) |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (4,816 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares of common stock outstanding – basic |  |  | 899,354,931 |  |  |  | 891,762,280 |  |  |  | 894,366,300 |  |  |  | 891,762,280 |
Dilutive impact of Gryphon Warrants |  |  | 134,495 |  |  |  | — |  |  |  | — |  |  |  | — |
Weighted average shares of common stock outstanding – diluted |  |  | 899,489,426 |  |  |  | 891,762,280 |  |  |  | 894,366,300 |  |  |  | 891,762,280 |
Net income (loss) per share of common stock: |  |  |  |  |  |  |  |  |  |  |  |
Basic from continuing operations (2) |  | $ | — |  |  | $ | — |  |  | $ | (0.10 | ) |  | $ | 0.19 |
Basic from discontinued operations (3) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.01 | )
Diluted from continuing operations (4) |  | $ | — |  |  | $ | — |  |  | $ | (0.10 | ) |  | $ | 0.19 |
Diluted from discontinued operations (5) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.01 | )
(1) Calculated as the net adjustment from warrant liability fair value remeasurement from Gryphon Warrants, net of tax (2) Calculated as net income from continuing operations – basic, divided by weighted average shares of common stock outstanding – basic (3) Calculated as loss from discontinued operations divided by weighted average shares of common stock outstanding – basic (4) Calculated as net income from continuing operations – diluted, divided by weighted average shares of common stock outstanding – diluted (5) Calculated as loss from discontinued operations divided by weighted average shares of common stock outstanding – diluted

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration